argenx

Foundation date

04/09/2009

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.

Upcoming events

Latest news

  • Celyad Oncology appoints Georges Rawadi as its new CEO

    Tuesday March 28th 2023

  • BioLizard appoints Paul Vauterin as Chief Technology Officer

    Monday March 27th 2023

  • ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI

    Monday March 27th 2023

Jobs by argenx